{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T20:24:21Z","timestamp":1780777461162,"version":"3.54.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jns-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.jns.2017.09.039","type":"journal-article","created":{"date-parts":[[2017,9,28]],"date-time":"2017-09-28T16:18:56Z","timestamp":1506615536000},"page":"91-95","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"special_numbering":"C","title":["CSF biomarkers \u03b2-amyloid, tau proteins and a-synuclein in the differential diagnosis of Parkinson-plus syndromes"],"prefix":"10.1016","volume":"382","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7432-5009","authenticated-orcid":false,"given":"Vasilios C.","family":"Constantinides","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George P.","family":"Paraskevas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Emmanouilidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Petropoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Bougea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kostas","family":"Vekrellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Evdokimidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleftherios","family":"Stamboulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Kapaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jns.2017.09.039_bb0005","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","article-title":"Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases","volume":"55","author":"Hughes","year":"1992","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"2","key":"10.1016\/j.jns.2017.09.039_bb0010","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/mds.10680","article-title":"Accuracy of clinical diagnosis of progressive supranuclear palsy","volume":"19","author":"Osaki","year":"2004","journal-title":"Mov. Disord."},{"issue":"15","key":"10.1016\/j.jns.2017.09.039_bb0015","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1002\/mds.22826","article-title":"A validation exercise on the new consensus criteria for multiple system atrophy","volume":"24","author":"Osaki","year":"2009","journal-title":"Mov. Disord."},{"issue":"Pt 7","key":"10.1016\/j.jns.2017.09.039_bb0020","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1093\/brain\/awq123","article-title":"Does corticobasal degeneration exist? A clinicopathological re-evaluation","volume":"133","author":"Ling","year":"2010","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.jns.2017.09.039_bb0025","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement."},{"issue":"9127","key":"10.1016\/j.jns.2017.09.039_bb0030","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(05)79256-4","article-title":"Multiple-system atrophy: a new alpha-synuclein disease?","volume":"352","author":"Gai","year":"1998","journal-title":"Lancet"},{"issue":"6645","key":"10.1016\/j.jns.2017.09.039_bb0035","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","article-title":"Alpha-synuclein in Lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.jns.2017.09.039_bb0040","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.expneurol.2008.06.004","article-title":"Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration","volume":"213","author":"Mollenhauer","year":"2008","journal-title":"Exp. Neurol."},{"issue":"1","key":"10.1016\/j.jns.2017.09.039_bb0045","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s004150050173","article-title":"Increased CSF tau protein in corticobasal degeneration","volume":"245","author":"Mitani","year":"1998","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.jns.2017.09.039_bb0050","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0022-510X(00)00480-9","article-title":"Diagnostic significance of tau protein in cerebrospinal fluid from patients with corticobasal degeneration or progressive supranuclear palsy","volume":"183","author":"Urakami","year":"2001","journal-title":"J. Neurol. Sci."},{"issue":"7","key":"10.1016\/j.jns.2017.09.039_bb0055","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s00702-007-0629-4","article-title":"Tauopathies and synucleinopathies: do cerebrospinal fluid beta-amyloid peptides reflect disease-specific pathogenesis?","volume":"114","author":"Mollenhauer","year":"2007","journal-title":"J. Neural Transm."},{"issue":"1","key":"10.1016\/j.jns.2017.09.039_bb0060","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/mds.23341","article-title":"Cerebrospinal fluid tau and phosphorylated tau protein are elevated in corticobasal syndrome","volume":"26","author":"Aerts","year":"2011","journal-title":"Mov. Disord."},{"issue":"11","key":"10.1016\/j.jns.2017.09.039_bb0065","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1001\/archneurol.2012.1654","article-title":"Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and\/or parkinsonian disorders","volume":"69","author":"Hall","year":"2012","journal-title":"Arch. Neurol."},{"issue":"1","key":"10.1016\/j.jns.2017.09.039_bb0070","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.parkreldis.2013.09.003","article-title":"CSF levels of DJ-1 and tau distinguish MSA patients from PD patients and controls","volume":"20","author":"Herbert","year":"2014","journal-title":"Parkinsonism Relat. Disord."},{"issue":"2","key":"10.1016\/j.jns.2017.09.039_bb0075","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/mds.10321","article-title":"Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy","volume":"18","author":"Holmberg","year":"2003","journal-title":"Mov. Disord."},{"issue":"2","key":"10.1016\/j.jns.2017.09.039_bb0080","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/mds.10687","article-title":"Cerebrospinal fluid Abeta42 levels in multiple system atrophy","volume":"19","author":"Verbeek","year":"2004","journal-title":"Mov. Disord."},{"issue":"11","key":"10.1016\/j.jns.2017.09.039_bb0085","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1136\/jnnp-2014-309562","article-title":"A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes","volume":"86","author":"Magdalinou","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"3","key":"10.1016\/j.jns.2017.09.039_bb0090","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S1474-4422(11)70014-X","article-title":"alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study","volume":"10","author":"Mollenhauer","year":"2011","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.jns.2017.09.039_bb0095","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2217\/bmm.12.46","article-title":"Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update","volume":"6","author":"del Campo","year":"2012","journal-title":"Biomark. Med"},{"issue":"1","key":"10.1016\/j.jns.2017.09.039_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/WNL.47.1.1","article-title":"Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop","volume":"47","author":"Litvan","year":"1996","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.jns.2017.09.039_bb0105","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1212\/WNL.0b013e31827f0fd1","article-title":"Criteria for the diagnosis of corticobasal degeneration","volume":"80","author":"Armstrong","year":"2013","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.jns.2017.09.039_bb0110","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1212\/01.wnl.0000324625.00404.15","article-title":"Second consensus statement on the diagnosis of multiple system atrophy","volume":"71","author":"Gilman","year":"2008","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.jns.2017.09.039_bb0115","doi-asserted-by":"crossref","first-page":"e81654","DOI":"10.1371\/journal.pone.0081654","article-title":"The diagnostic value of CSF alpha-synuclein in the differential diagnosis of dementia with Lewy bodies vs. normal subjects and patients with Alzheimer's disease","volume":"8","author":"Kapaki","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.jns.2017.09.039_bb0120","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1212\/WNL.53.4.795","article-title":"Pathologic heterogeneity in clinically diagnosed corticobasal degeneration","volume":"53","author":"Boeve","year":"1999","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.jns.2017.09.039_bb0125","first-page":"399","article-title":"Cortical Alzheimer type pathology does not influence tau pathology in progressive supranuclear palsy","volume":"2","author":"Oshima","year":"2009","journal-title":"Int. J. Clin. Exp. Pathol."},{"issue":"9","key":"10.1016\/j.jns.2017.09.039_bb0130","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/mds.10488","article-title":"Diagnostic accuracy of progressive supranuclear palsy in the Society for Progressive Supranuclear Palsy brain bank","volume":"18","author":"Josephs","year":"2003","journal-title":"Mov. Disord."},{"issue":"9","key":"10.1016\/j.jns.2017.09.039_bb0135","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1136\/jnnp.74.9.1210","article-title":"A prospective study of CSF markers in 250 patients with possible Creutzfeldt-Jakob disease","volume":"74","author":"Van Everbroeck","year":"2003","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"5","key":"10.1016\/j.jns.2017.09.039_bb0140","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1177\/1352458512460603","article-title":"Cerebrospinal fluid biomarkers of beta-amyloid metabolism in multiple sclerosis","volume":"19","author":"Augutis","year":"2013","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.jns.2017.09.039_bb0145","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/alzrt109","article-title":"Examining the mechanisms that link beta-amyloid and alpha-synuclein pathologies","volume":"4","author":"Marsh","year":"2012","journal-title":"Alzheimers Res. Ther."},{"issue":"2","key":"10.1016\/j.jns.2017.09.039_bb0150","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000112832","article-title":"Red blood cells are the major source of alpha-synuclein in blood","volume":"5","author":"Barbour","year":"2008","journal-title":"Neurodegener. Dis."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X17343459?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X17343459?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,27]],"date-time":"2018-08-27T03:05:45Z","timestamp":1535339145000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X17343459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":30,"alternative-id":["S0022510X17343459"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2017.09.039","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CSF biomarkers \u03b2-amyloid, tau proteins and a-synuclein in the differential diagnosis of Parkinson-plus syndromes","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2017.09.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}